---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-001254"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T08:56:46.483436+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Mirum reports Q2 revenue $37.5M, LIVMARLI sales $32.5M; acquires CHENODAL/CHOLBAM for $210M

## Summary
- Q2 total revenue $37.5M (incl $5M license); LIVMARLI net sales $32.5M, up 86% YoY.
- Acquiring CHENODAL and CHOLBAM from Travere for $210M upfront + up to $235M milestones.
- Entered $210M private placement to fund acquisition; closed $316.3M convertible notes at 4% due 2029.
- Pipeline readouts H2 2023: EMBARK (biliary atresia), volixibat PSC/PBC, CHENODAL RESTORE.
- Cash $330M as of June 30; repurchased 9.75% royalty obligation.

## SEC filing metadata
- accession: 0001157523-23-001254
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000115752323001254/0001157523-23-001254-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000115752323001254/a53507837.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-001254
- JSON: https://secwatch.observer/filing/0001157523-23-001254.json
- Plain text: https://secwatch.observer/filing/0001157523-23-001254.txt

## Key facts
- Earnings Releases
  Mirum Pharmaceuticals, Inc. reported the quarter ended June 30, 2023 results: revenue $37.5 million.
  - Period: the quarter ended June 30, 2023
  - Revenue: $37.5 million
  - Result: reported results
  source text: Total revenue for the quarter ended June 30, 2023 was $37.5 million, including $5.0 million of license revenue, compared to $17.5 million in total revenue for the quarter ended June 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759425/000115752323001254/0001157523-23-001254-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.